This paper should be cited as:
Gol Mohammadi, R. Tabaraei, A. Abbasi, A. Khademi, N. Mahdavian, B. Javid, N.
Moradi, A.
Drug-Resistant HIV-1 RT Gene Mutations in Patients under Treatment
with Antiretroviral Drugs (HAART) in Iran
Gol Mohammadi, R. (MSc)1, Tabaraei, A.
(PhD)2, Abbasi, A. (MD)3, Khademi, N. (MD)4, Mahdavian, B. (MD)5, Javid, N.
(MSc)6, Kaleji, H. (MSc)7, Alikhani, A. (BSc)8, Bazoori, M. (BSc)9, Moradi, A.
(PhD)10
1. MSc of Medical Virology, School of Medicine, Golestan
University of Medical Sciences, Gorgan, Iran
2. Associate Professor of Virology, Infectious Diseases
Research Center, Golestan University of Medical Sciences, Gorgan, Iran
3. Associate Professor of Infectious Diseases, Infectious
Diseases Research Center, Golestan University of Medical Sciences, Gorgan, Iran
4. General Practitioner, Kermanshah University of Medical
Sciences, Kermanshah, Iran
5. Infectious Disease Specialist, Kermanshah University of
Medical Sciences, Kermanshah, Iran
6. MSc of Microbiology, Department of Microbiology, Golestan
University of Medical Sciences, Gorgan, Iran
7. MSc of Virology, School of Medicine, Golestan University of
Medical Sciences, Gorgan, Iran
8. BSc of Medical Laboratory, Consultation center of behavioral
disorders, Kermanshah University of Medical Sciences, Kermanshah, Iran
9. BSc of Microbiology, School of Medicine, Golestan University
of Medical Sciences, Gorgan, Iran
10 Professor of Medical Virology, Department of Microbiology,
School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran
Abstract
Background and Objective:
Highly Active
Antiretroviral Therapy (HAART) can
effectively prevent the progression of HIV-1 replication and increase life
expectancy. There are numerous causes of treatment failure and the leading one
is drug resistance. Thus, we aimed to determine the HIV RT gene drug resistance
mutations in patients treated with antiretroviral medications.
Material and Methods: In this cross
- sectional study, venous blood was taken from 130 HIV-positive patients
treated with antiretroviral medications. In order to determine
drug resistance mutations, RT-PCR and PCR steps were performed using RT gene
specific primers. Subtypes and mutations in the virus genome were determined
using the Stanford HIV drug resistance sequence database.
Results: In 122 treating
patients, most of the major mutations were associated with nucleoside and
non-nucleoside drugs. subtype A in 66.4%, subtype D in 26.2% and subtype B in
7.4% of the participants were reported. They were resistant to Nucleoside RT
Inhibitor drugs (23.7%) and Non-Nucleoside RT Inhibitor drugs(30.3%). The
highest were related to Nevirapine (21.3%) and Efavirenz (19.7%) and the lowest
to both Tenofovir and Zidovudine (91.5%).
Conclusion: The use of
two nucleoside RT inhibitor drugs combined with one protease inhibitor drug
could be effective in the treatment of HAART.
Key
words: HIV, Nucleoside RT Inhibitor, Non- Nucleoside RT
Inhibitor